MedTrace Logo

Effects of Calamansi on Blood Glucose and Insulin Levels

NCT07587905 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-05-15

No results posted yet for this study

Summary

Fifty-four healthy sedentary male and female participants aged 18-30 years will be recruited for this study. Participants will be randomly assigned to one of two groups: a control group receiving placebo MMC capsules (n = 27) or a calamansi capsule supplementation group (n = 27). All participants will undergo health screening procedures, including medical history assessment, mental health questionnaire evaluation, and measurements of vital signs, height, body weight, and body composition. Venous blood samples will subsequently be collected to determine blood glucose, insulin, creatinine, alanine aminotransferase (ALT), and malondialdehyde (MDA) levels. These assessments will be performed at three time points: 1) before capsule supplementation (baseline), 2) following a single dose of capsule supplementation, and 3) after 12 weeks of supplementation.

Conditions

  • Calamansi Powder Capsule Supplementation

Interventions

OTHER

MMC powder capsule

Each capsule contains MMC powder for 500 mg

DIETARY_SUPPLEMENT

Calamansi powder capsule

Each capsule contains calamansi powder for 500 mg

Sponsors & Collaborators

  • Burapha University

    lead OTHER

Principal Investigators

  • Piyapong Prasertsri, Ph.D. · Faculty of Allied Health Sciences, Burapha University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-12-31
Completion
2027-01-31

Countries

  • Thailand

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07587905 on ClinicalTrials.gov